Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123,180,519
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
67,671,701
-
Shares change
-
+1,114,702
-
Total reported value, excl. options
-
$311,885,548
-
Value change
-
+$10,809,324
-
Put/Call ratio
-
48.3%
-
Number of buys
-
64
-
Number of sells
-
-60
-
Price
-
$4.61
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q1 2021
151 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2021.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67,671,701 shares
of 123,180,519 outstanding shares and own 54.9% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (10,000,000 shares), STATE STREET CORP (8,933,983 shares), BlackRock Inc. (8,274,686 shares), VANGUARD GROUP INC (5,586,295 shares), ROYCE & ASSOCIATES LP (3,249,650 shares), PRUDENTIAL FINANCIAL INC (2,749,179 shares), GEODE CAPITAL MANAGEMENT, LLC (1,766,865 shares), GOLDMAN SACHS GROUP INC (1,421,993 shares), LSV ASSET MANAGEMENT (1,410,737 shares), and ACADIAN ASSET MANAGEMENT LLC (1,204,678 shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.